Repeatable battery for the assessment of neuropsychological status and its relationship to biomarkers of Alzheimer’s disease

Duff, Kevin; Suhrie, Kayla R; Hammers, Dustin B.; Dixon, Ava; King, Jace B.; Koppelmans, Vincent; Hoffman, John M.

doi:10.1080/13854046.2021.1995050

Cited by 10 publications

(6 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16 Previous studies suggest that RBANS DMI may be a suitable instrument to assess progression in patients with early AD due to its sensitivity in predicting functional capacity in patients with AD and mild cognitive impairment due to AD, 3 and its correlation with known AD biomarkers. [6][7][8] However, when analyzing the trajectories in participants with RBANS DMI between 85 and 95 at baseline, there was no clear trend in change at 6 or 12 months in these data. With an estimated 15% of participants progressing to meet the RBANS DMI cutoff of ≤ 85 at 6 months, 7 patients would need to rescreen.…”

Section: Discussionmentioning

confidence: 85%

“…The RBANS, particularly the Delayed Memory Index (DMI), can be used to enrich for the study of AD pathology 6–8 . In AD clinical trials that use RBANS DMI as part of the inclusion criteria, an RBANS DMI score ≤85 is typically used to select a patient population with cognitive impairment and an increased likelihood of having amyloid positivity.…”

mentioning

confidence: 99%

“…[3][4][5] The RBANS, particularly the Delayed Memory Index (DMI), can be used to enrich for the study of AD pathology. [6][7][8] In AD clinical trials that use RBANS DMI as part of the inclusion criteria, an RBANS DMI score ≤ 85 is typically used to select a patient population with cognitive impairment and an increased likelihood of having amyloid positivity. The RBANS DMI is relatively brief to administer, thus avoiding other screening procedures such as amyloid positron emission tomography scans and lumbar punctures.…”

mentioning

confidence: 99%

“…The RBANS DMI is relatively brief to administer, thus avoiding other screening procedures such as amyloid positron emission tomography scans and lumbar punctures. 3,8 Trial investigators may consider some patients who do not meet the RBANS DMI ≤ 85 cutoff to otherwise have AD, but it is unclear if they would meet the eligibility criteria if rescreened for RBANS DMI at a later date. It has been proposed that allowing for the rescreening of participants who failed screening based on the RBANS DMI could help to reduce the burden of trial recruitment.…”

mentioning

confidence: 99%

“…In AD clinical trials that use RBANS DMI as part of the inclusion criteria, an RBANS DMI score ≤85 is typically used to select a patient population with cognitive impairment and an increased likelihood of having amyloid positivity. The RBANS DMI is relatively brief to administer, thus avoiding other screening procedures such as amyloid positron emission tomography scans and lumbar punctures 3,8 . Trial investigators may consider some patients who do not meet the RBANS DMI ≤85 cutoff to otherwise have AD, but it is unclear if they would meet the eligibility criteria if rescreened for RBANS DMI at a later date.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Rescreening on RBANS Delayed Memory Index? Forget About It!

Sabbagh,

Michalak,

Thim Hansen

et al. 2024

Alzheimer Disease &Amp; Associated Disorders

View full text Add to dashboard Cite

Objective: To assess the value of rescreening patients with Alzheimer’s disease who do not meet the inclusion criteria for the Repeatable Battery for the Assessment of Neuropsychological Status Delayed Memory Index (RBANS DMI) at the initial assessment. Patients and Methods: Participants (aged 50–85 years, without dementia, Mini-Mental State Examination score ≥22, valid Clinical Dementia Rating [CDR] global score, and amyloid status at baseline) were identified in the European Prevention of Alzheimer’s Dementia database. Changes from baseline in RBANS DMI were estimated using a mixed model for repeated measurements. Logistic regressions were used to estimate the probability of participants with baseline RBANS DMI 86–95 having RBANS DMI ≤85, CDR global score ≥0.5, and amyloid positivity at 6 and 12 months. Results: There was significant variability in the change in RBANS DMI scores over time (median change at 6 months: 2.0). An estimated 15% of participants with RBANS DMI 86–95 at baseline progressed to ≤85 at 6 months; 8% also achieved CDR global score ≥0.5 and 5% were also amyloid positive. Conclusions: The results from our analysis indicate that there is limited value in rescreening patients based on their initial RBANS DMI score.

show abstract